after you have consented to join the trial, you will be assigned by a computer system to receive either the study medication or a matching placebo. the assignment is random and you will not know which one you receive.

if you are assigned to the active group, you will receive oreNCIA 1750 mg (abatacept) prepared as a solution for infusion. the medication is given by intravenous infusion, which means it is delivered into a vein using a small pump over a period of time. the dose is a single infusion administered early after randomisation.

if you are assigned to the control group, you will receive normal saline in a volume that matches the active infusion. this is also given by intravenous infusion in the same manner.

while the infusion is being administered, clinical staff will observe you for any immediate reactions. vital signs such as heart rate, blood pressure, and breathing will be checked regularly.

after the infusion is completed, you will remain under observation for a short period. staff will continue to monitor for any delayed reactions or side effects.

starting the day after infusion, you will be evaluated each day for up to 60 days. the assessment uses the days to recovery scale (drs‑60), which records whether you have recovered, remain unwell, or have experienced serious outcomes such as death.

the daily assessment includes checks of your breathing, need for additional oxygen, and overall health status.

in addition to daily assessments, you will have specific follow‑up visits (for example on day 7, day 14, day 30, and day 60). during these visits, staff will record any adverse events, review your recovery progress, and collect safety data.

on day 60, the trial period ends for you. a final evaluation will be performed to determine your recovery status and to document any outcomes that occurred during the study.